Beaufort Securities retained Tissue Regenix Group PLC (LON:TRX) to Speculative Buy in a statement released earlier today.
- Updated: October 15, 2016
Yesterday Tissue Regenix Group PLC (LON:TRX) traded 0.00% even at 16.50GBX. The company’s 50-day moving average is 19.13GBX and its 200-day moving average is 19.36GBX. The last stock price is down -7.66% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,113,726 shares of TRX traded, up from an average trading volume of 255,058
Beaufort Securities has retained Tissue Regenix Group PLC (LON:TRX) to Speculative Buy in a statement released on 10/13/2016.
With a total market value of 0 GBX, Tissue Regenix Group PLC has with a 52 week low of 12.70GBX and a 52 week high of 22.50GBX .
In addition to Beaufort Securities reporting its stock price target, a total of 1 broker has issued a research note on the company. The average stock price target is 40.00GBX with one analyst rating the company a strong buy, zero analysts rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly zero brokerages rating the company a sell.
General Company Details For Tissue Regenix Group PLC (LON:TRX)
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.